JP6171333B2 - 安定化したビタミンd類標準液 - Google Patents
安定化したビタミンd類標準液 Download PDFInfo
- Publication number
- JP6171333B2 JP6171333B2 JP2012283327A JP2012283327A JP6171333B2 JP 6171333 B2 JP6171333 B2 JP 6171333B2 JP 2012283327 A JP2012283327 A JP 2012283327A JP 2012283327 A JP2012283327 A JP 2012283327A JP 6171333 B2 JP6171333 B2 JP 6171333B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- standard solution
- human
- hydroxyvitamin
- standard
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Peptides Or Proteins (AREA)
Description
(1)以下に示す各溶液に、25−ヒドロキシビタミンD3を終濃度20ng/mLまたは80ng/mLとなるよう添加することで、ビタミンD類標準液を調製した。
試薬B:5%ウシ血清アルブミンを含む50mMリン酸緩衝液(pH7.0)
試薬C:5%ウシ血清アルブミンを含む50mMトリス塩酸緩衝液(pH7.5)
試薬D:5%ウシ血清アルブミンを含む50mMトリス塩酸緩衝液(pH8.0)
試薬E:5%ウシ血清アルブミンを含む50mMトリス塩酸緩衝液(pH8.5)
(2)(1)で調製したビタミンD類標準品各1mLをガラス製容器に分注し、凍結乾燥した。
(3)各凍結乾燥体に蒸留水1mLを加えて再溶解し、4℃(保存時を想定)または35℃(測定時を想定)で16時間保存した後、全自動エンザイムイムノアッセイ装置(AIA−2000、東ソー社製)と当該装置用25−ヒドロキシビタミンD免疫測定試薬とを用いて各標準品を測定し、当該試薬に含まれる基質(4−メチルウンベリフェロン)からの蛍光強度増加速度[nM/s]を求めた。
(35℃で保存した標準液の蛍光強度増加速度)÷(4℃で保存した標準液の蛍
光強度増加速度)×100
Claims (4)
- 一定濃度のビタミンD類を含むビタミンD類標準液であって、ヒト以外に由来したタンパク質をさらに含み、かつそのpHが7.5以上であり、ヒト以外に由来したタンパク質がウシ血清アルブミンであり、抗原抗体反応を利用した免疫測定用である、前記標準液。
- ビタミンD類が25−ヒドロキシビタミンD2または25−ヒドロキシビタミンD3である、請求項1に記載の標準液。
- 請求項1または2に記載の標準液を凍結乾燥して得られる、凍結乾燥体。
- 請求項1または2に記載の標準液を用いて、抗原抗体反応を利用した免疫測定によりビタミンD類を測定する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012283327A JP6171333B2 (ja) | 2012-12-26 | 2012-12-26 | 安定化したビタミンd類標準液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012283327A JP6171333B2 (ja) | 2012-12-26 | 2012-12-26 | 安定化したビタミンd類標準液 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014126453A JP2014126453A (ja) | 2014-07-07 |
JP6171333B2 true JP6171333B2 (ja) | 2017-08-02 |
Family
ID=51406066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012283327A Expired - Fee Related JP6171333B2 (ja) | 2012-12-26 | 2012-12-26 | 安定化したビタミンd類標準液 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6171333B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109187781A (zh) * | 2018-09-03 | 2019-01-11 | 美康生物科技股份有限公司 | 血清型冻干粉25-羟基维生素d3和d2质量控制物质及其制备方法 |
CN112305092A (zh) * | 2019-07-31 | 2021-02-02 | 广州金域医学检验中心有限公司 | 25-羟基维生素d的校准品基质、制备方法及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456553A (en) * | 1982-05-07 | 1984-06-26 | Teijin Limited | Vitamin D3 derivatives, process for preparation thereof, and antigens comprising said derivatives to be used for preparation of antibodies for immunochemical assay and antibodies prepared therefrom |
GB0029729D0 (en) * | 2000-12-06 | 2001-01-17 | Ids Ltd | Method for detection of vitamin D metabolites |
CN101467048B (zh) * | 2006-06-06 | 2014-04-02 | 霍夫曼-拉罗奇有限公司 | 改良的维生素d测量方法 |
DK2126586T3 (da) * | 2007-02-01 | 2010-10-11 | Immundiagnostik Ag | Direkte bestemmelse af vitamin D i serum eller plasma |
BR112012030239A2 (pt) * | 2010-06-24 | 2015-09-08 | Prayon S A | composto ativo estabilizado |
-
2012
- 2012-12-26 JP JP2012283327A patent/JP6171333B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2014126453A (ja) | 2014-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lohmann et al. | Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells | |
Mellenthin et al. | Association between serum vitamin D concentrations and inflammatory markers in the general adult population | |
Thiolliere et al. | Epidemiology and outcome of thrombocytopenic patients in the intensive care unit: results of a prospective multicenter study | |
Ogawa et al. | Zinc and skin biology | |
Heaney et al. | Quantifying the vitamin D economy | |
Kimball et al. | Signal transduction pathways involved in the regulation of protein synthesis by insulin in L6 myoblasts | |
Powe et al. | First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia | |
CN103163306B (zh) | 25羟维生素d检测试剂盒及其制备方法 | |
McNally et al. | Impact of anesthesia and surgery for congenital heart disease on the vitamin d status of infants and children: a prospective longitudinal study | |
Lynch | Case studies: iron | |
CN104673747A (zh) | 一种血小板裂解液的制备方法及其应用 | |
Chou et al. | Ex vivo expansion of bovine corneal endothelial cells in xeno-free medium supplemented with platelet releasate | |
JP6171333B2 (ja) | 安定化したビタミンd類標準液 | |
Zhao et al. | Dynamic changes in serum 25-hydroxyvitamin D during pregnancy and lack of effect on thyroid parameters | |
Shea et al. | Perspective: evidence before enthusiasm—a critical review of the potential cardiovascular benefits of vitamin K | |
Baxter et al. | Dietary toxicity of calcium β-hydroxy-β-methyl butyrate (CaHMB) | |
Ji et al. | Deciphering the combined effect of bone morphogenetic protein 6 and calcium phosphate on bone formation capacity of periosteum derived cell-based tissue engineering constructs | |
CN105247372A (zh) | 用于测定维生素d代谢物的方法和试剂 | |
Huang et al. | Bioactive recombinant human lactoferrin, derived from rice, stimulates mammalian cell growth | |
Fan et al. | Elevated p-CREB-2 (ser 245) expression is potentially associated with carcinogenesis and development of breast carcinoma | |
Romanello et al. | Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment | |
Ceglia et al. | Effects of alkali supplementation and vitamin D insufficiency on rat skeletal muscle | |
Tanaka et al. | Hypoxic preconditioning of human cardiosphere-derived cell sheets enhances cellular functions via activation of the PI3K/Akt/mTOR/HIF-1α pathway | |
JP6520948B2 (ja) | 蛋白質安定化剤及び蛋白質安定化方法 | |
Hewison et al. | Vitamin D insufficiency and skeletal development in utero |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151118 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161108 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170307 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170414 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170619 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 6171333 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
LAPS | Cancellation because of no payment of annual fees |